Post by
somweyungguy on Nov 21, 2015 11:16am
The Endo trial debacle....new questions from ADCOM....
I was told directly by the CEO of the "old ticker symbol" ( see Spectral, Trimel and Bioniche ) that the Endo trial failed because Mitomycin was a "poor option" for bladder cancer patients and therefore we had a "hard time" recruiting because 50% new drug ( Urocidin / MCNA ) or 50% Mitiomycin was NOT an appealing trial to enter....I bought that...
Now at the FDA meetings we're told that the trial went poorly because.."there was a shortage of Mitimycin"....interesting, so what was the reason...let's assume everyone is telling the truth and the answer was a "hybrid"...both
The TOXIC make-up of BCG and the EXTREME shortages of the drug were NOT discussed at ADCOMM...I too wonder why.
The US based LADENBURG THALMANN ( google Dr. Frost - health care investing ACE ) has not even had a chance to trade one of the 109MM shares...YET....I like this A LOT and believe this 3rd TAX LOSS SEASON TRAGEDY is no small COIN-CIDENCE
What do you think Beecher? ; - )
Comment by
DamnYankees on Nov 21, 2015 11:26am
Somwey, I think that the FDA appoints the nation's opinion leaders and brightest minds to decide to deprive its citizens suffering from bladder cancer an extension to their lives, and their right to choose to live, so you can post in big green font on a foreign stock board That is what I think. you asked!
Comment by
investderp on Nov 21, 2015 1:05pm
MCC Mycobacterial Cell Wall-DNA Complex MCNA Mycobacterium phlei Cell Wall-Nucleic Acid Complex "c) Endo chose MCC as they believed Valstar would have enrollment problems and not acceptable as a comparator to potential enrolllees" I think you're calling Mitomcyin C 'MCC' which it is not.